External Committees

Advisory Board

The ICER Advisory Board is comprised of Flagship members of ICER’s Policy Leadership Forum and other select stakeholders. The Advisory Board meets annually with ICER’s Governance Board to provide guidance on ICER’s overall portfolio of activities and strategic plan. The Advisory Board provides perspective and advice to ICER on how it can best fulfill its mission, but the Advisory Board has no direct governance role.

  • Lora Armstrong, PharmD, Vice President, Medical Affairs, CVS Health
  • Carmella Bocchino, RN, MBA , President and CEO, CRB Strategies, LLC
  • Anne B. Docimo, MD, MBA, Chief Medical Officer, UnitedHealthcare Clinical Services
  • Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
  • Tony Grillo, PharmD, Vice President, Financial Analysis and Forecasting, Express Scripts
  • Beth Hamilton, MBA, Vice President, Global Oncology Market Access & Pricing (OMAP), AstraZeneca
  • Kyle Hvidsten, Head, Specialty Care Health Economics & Value Assessment, Sanofi
  • Andreas Kuznik, PhD, Executive Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc.
  • Mark McClellan, MD, PhD, Founding Director, Duke-Margolis Center for Health Policy, Duke University
  • Sean McElligott, Executive Director and Head, US Health Economics Outcomes Research, Novartis
  • Megan McIntyre, PharmD, Vice President, Pharmacy and Clinical Consulting, Premera Blue Cross
  • Russ Montgomery, PhD, Senior Director, US Value Assessment Strategy, GlaxoSmithKline
  • Yeesha Poon, PhD, MBA, Director, Global Market Access & Health Economics, Abbott
  • Jon Rosen, PharmD, Director of Trend and Pipeline, Humana
  • Gail Ryan, PharmD, Director of Pharmaceutical Transformation, Point32Health
  • David R. Strutton, PhD, Vice President, Global Pharmaceuticals and Policy Evidence Research, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc.
  • Sean D. Sullivan, PhD, Professor and Dean, University of Washington School of Pharmacy
  • Heidi C. Waters, PhD, MBA, Senior Director, Policy Research, Global Value & Real World Evidence, Otsuka Pharmaceutical
  • Kimberly Westrich, Chief Strategy Officer, National Pharmaceutical Council
  • Sarah Yoon, Director of Drug Information, Centene Pharmacy Services

    Methods Advisory Group

    ICER’s Methods Advisory Group (MAG) meets three times per year to provide guidance on ICER’s methods for health technology assessments and other evaluations. In the past few years, the MAG has helped to shape a data in-confidence policy, develop a pilot for a model transparency program, and comment on the process and methods for ICER’s report evaluating price increases for high impact drugs.

        • Abbott
        • AstraZeneca
        • Centene Pharmacy Services
        • CVS Caremark
        • Elevance Health
        • Express Scripts
        • GlaxoSmithKline
        • Humana
        • Kaiser Permanente
        • Merck & Co.
        • National Pharmaceutical Council
        • Novartis
        • Otsuka Pharmaceutical
        • Point32Health
        • Premera Blue Cross
        • Prime Therapeutics
        • Regeneron Pharmaceuticals, Inc.
        • Sanofi
        • UnitedHealthcare